<SEC-DOCUMENT>0001104659-22-030888.txt : 20220307
<SEC-HEADER>0001104659-22-030888.hdr.sgml : 20220307
<ACCEPTANCE-DATETIME>20220307083037
ACCESSION NUMBER:		0001104659-22-030888
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220307
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220307
DATE AS OF CHANGE:		20220307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES, INC.
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19731
		FILM NUMBER:		22716359

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILEAD SCIENCES INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm228518d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:GILD="http://gilead.com/20220307">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_GILD_gilead.com_20220307 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20220307_20220307 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0000882095 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-03-07to2022-03-07" name="dei:EntityCentralIndexKey">0000882095</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-03-07to2022-03-07" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="gild-20220307.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-03-07to2022-03-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-07</xbrli:startDate>
        <xbrli:endDate>2022-03-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.55pt; text-align: center"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 2.6pt; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center"><b>FORM <span id="xdx_90E_edei--DocumentType_c20220307__20220307_zi0J8orIT9Vd"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.1pt 0pt 176.35pt; text-align: center; text-indent: -0.05pt"><b>Pursuant
to Section 13 or 15(d) of<br />
 The Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center">DATE OF REPORT (DATE OF EARLIEST
EVENT REPORTED): <b><span id="xdx_908_edei--DocumentPeriodEndDate_c20220307__20220307_z1Fex59zXGb8"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 7, 2022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center"><b><span id="xdx_907_edei--EntityRegistrantName_c20220307__20220307_zrW0KxGToTu1"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" name="dei:EntityRegistrantName">GILEAD SCIENCES, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.6pt; text-align: center">(Exact name of registrant
as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 33%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20220307__20220307_zPiiokne02Cb"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 34%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90D_edei--EntityFileNumber_c20220307__20220307_zPrfpWP0dJc6"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" name="dei:EntityFileNumber">0-19731</ix:nonNumeric></span></b></span></td>
    <td style="width: 33%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20220307__20220307_z53rQUk0Qi48"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" name="dei:EntityTaxIdentificationNumber">94-3047598</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or Other Jurisdiction<br />
of Incorporation)</span></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission File No.)</span></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(IRS Employer<br />
Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center"><span id="xdx_90B_edei--EntityAddressAddressLine1_c20220307__20220307_zavUaxXF47Sl"><b><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" name="dei:EntityAddressAddressLine1">333
Lakeside Drive</ix:nonNumeric></b></span><b>, <span id="xdx_900_edei--EntityAddressCityOrTown_c20220307__20220307_zILWwfDugnpl"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" name="dei:EntityAddressCityOrTown">Foster City</ix:nonNumeric></span></b><b>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20220307__20220307_z9NkV70BQ6X2"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center">(Address of Principal Executive
Offices)</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center"><b>&#160;</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center"><b><span id="xdx_902_edei--EntityAddressPostalZipCode_c20220307__20220307_zgVGog0rk44f"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" name="dei:EntityAddressPostalZipCode">94404</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center">(Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center"><b><span id="xdx_90B_edei--CityAreaCode_c20220307__20220307_zrUSzkESXF7h"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" name="dei:CityAreaCode">650</ix:nonNumeric></span>-<span id="xdx_900_edei--LocalPhoneNumber_c20220307__20220307_zYdnoc6AcDj"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" name="dei:LocalPhoneNumber">574-3000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.55pt; text-align: center">(Registrant&#8217;s Telephone
Number, Including Area Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.55pt; text-align: center">(Former Name or Former Address,
if Changed Since Last Report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.75pt 0pt 5.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90A_edei--WrittenCommunications_c20220307__20220307_zQ7oa8eGxNd7"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_903_edei--SolicitingMaterial_c20220307__20220307_zzoVXFnpsmp7"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_904_edei--PreCommencementTenderOffer_c20220307__20220307_zU5wVWRCsmaj"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20220307__20220307_zPeWVYvPoyj8"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Securities registered pursuant to Section 12(b) of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Title of Each Class:</span></td>
    <td style="width: 2%; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Trading Symbol(s)</span></td>
    <td style="width: 2%; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 0.25in; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Name of Each Exchange on Which<br />
Registered</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--Security12bTitle_c20220307__20220307_zx5YBFngvyWi"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" name="dei:Security12bTitle">Common Stock, par value, $0.001 per share</ix:nonNumeric></span></b></span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_906_edei--TradingSymbol_c20220307__20220307_zpCHwLyRWQve"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" name="dei:TradingSymbol">GILD</ix:nonNumeric></span></b></span></td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-left: 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_900_edei--SecurityExchangeName_c20220307__20220307_zrEDZVUXHct1"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Global Select Market</ix:nonNumeric></span></b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">Emerging
growth company <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20220307__20220307_zodwsq0IiBtf"><ix:nonNumeric contextRef="From2022-03-07to2022-03-07" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-top: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#160;7.01</b></span><span style="font-size: 10pt">&#160;&#160;&#160;&#160;</span><b>Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
</span>March&#160;7, 2022, Gilead Sciences,&#160;Inc., a Delaware corporation (the &#8220;Company&#8221;), issued a press release announcing
certain results from the Phase 3 TROPiCS-02 study evaluating Trodelvy<sup>&#174;</sup> (sacituzumab govitecan-hziy) in patients with HR+/HER2-
metastatic breast cancer (the &#8220;Study Results&#8221;). A copy of the press release is filed as Exhibit&#160;99.1 to this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company provided additional information relating to the Study Results
in a TROPiCS-02 Questions and Answers document posted on its website at www.gilead.com. A copy of the TROPiCS-02 Questions and Answers
is filed as Exhibit&#160;99.2 to this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The information in Item 7.01 and Item 9.01
of this Form&#160;8-K and Exhibits 99.1 and 99.2 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18
of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities under that
section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act, regardless of any general incorporation language in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01</b></span>&#160;&#160;&#160;&#160;<b>Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following Exhibits 99.1 and 99.2 are furnished pursuant to this
Item 9.01.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 9%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Number</p></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="tm228518d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm228518d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, issued by Gilead Sciences,&#160;Inc. on March&#160;7, 2022</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="tm228518d1_ex99-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></a></td>
    <td>&#160;</td>
    <td><a href="tm228518d1_ex99-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TROPiCS-02 Questions and Answers, dated March&#160;7, 2022</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GILEAD SCIENCES,&#160;INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ </span><span style="text-transform: uppercase">Brett A. Pletcher</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brett A. Pletcher</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVP, Corporate Affairs, General Counsel and Corporate Secretary</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</span>&#160;&#160;&#160;&#160;March&#160;7,
2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFTdsKgkAQ/QL/YdjnMJPqwbeSisgiJKLXJadY0h2Z3Sw/qb9sVKLhwNzORamR2tDalMhwWeYZnLCqS+0Rcrwho72iMNLtLgHpOd6N86yt79efMCXRoGhm4VzLvWc2xmGRwCQex5FAhmQ6hcVeBd0/JXszBVpvdAnaFnBkqtmg19wODif9JktV2yedkZ0hK3ZhNLw/EEeTGA7U6Bfxw0GWpSoY9RWoDdOz7mKezlMFqxIryXKD9I/gC9JXSQU= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm228518d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;<IMG SRC="tm228518d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>CONTACTS: </B>Jacquie Ross,&nbsp;Investors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0; text-indent: 330.75pt"><U>investor_relations@gilead.com</U></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 348.75pt">Nathan Kaiser, U.S. Media</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 399pt">(650) 522-1853</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Karley Ura, Global Media</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(416) 858-0537</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PHASE 3 TROPiCS-02 STUDY MET THE PRIMARY ENDPOINT
OF PROGRESSION-</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FREE SURVIVAL IN LATE-LINE HR+/HER2- METASTATIC BREAST CANCER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&ndash; <B><I>Study Will Continue to Follow Patients
for Overall Survival, a Key Secondary Endpoint</I></B> &ndash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Foster City, Calif., March&nbsp;7, 2022 &ndash;</B>
Gilead Sciences,&nbsp;Inc. (Nasdaq: GILD) today announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy<SUP>&reg;</SUP>
(sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors
and two to four lines of chemotherapy. The study met its primary endpoint with a statistically significant improvement in progression-free
survival (PFS) versus physician&rsquo;s choice of chemotherapy. The trial targeted a 30% reduction in the risk of disease progression
or death. The primary endpoint results were consistent with those observed in the Phase 1/2 IMMU-132-01 study in a subset of HR+/HER2-
metastatic breast cancer patients.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>[1]</SUP></FONT> The
first interim analysis of the key secondary endpoint of overall survival in the TROPiCS-02 study demonstrated a trend in improvement for
overall survival. Patients will be followed for a subsequent overall survival analysis. The safety profile for Trodelvy was consistent
with prior studies, and no new safety concerns emerged in this patient population.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Trodelvy demonstrated consistent activity
in this difficult-to-treat patient population,&rdquo; said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. &ldquo;We are
evaluating the data and will explore potential pathways with regulatory authorities to bring Trodelvy to this group of patients. As we
work to expand the patient benefit of Trodelvy beyond its current indications for second-line metastatic triple-negative breast cancer
and accelerated approval in second-line metastatic bladder cancer, we are pursuing studies across multiple tumor types and earlier lines
of therapy.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;HR+/HER2-&nbsp;breast cancer accounts for
approximately 70% of all breast cancer cases.&nbsp;Patients with advanced&nbsp;breast&nbsp;cancer may eventually develop endocrine resistance,
then resistance to a limited set of sequential chemotherapy options,&rdquo;&nbsp;said Hope&nbsp;Rugo,&nbsp;MD, Professor of Medicine and
Director, Breast Oncology and Clinical Trials Education at the University of California San Francisco Comprehensive Cancer Center. &ldquo;These
data show the potential for Trodelvy to address an important unmet need for patients with HR+/HER2- metastatic breast cancer who have
been heavily pretreated.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Detailed results from TROPiCS-02 will be presented
at an upcoming medical conference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT>
Kalinsky et al, 2020</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-size: 10pt">Gilead Sciences,&nbsp;Inc. 333 Lakeside Drive Foster City, CA 94404 USA</FONT> <FONT STYLE="font-size: 10pt"><I><BR>
phone</I> 650 574 3000 <I>facsimile</I> 650 578 9264</FONT></TD>
    <TD STYLE="text-align: right; width: 50%"><FONT STYLE="font-size: 10pt">www.gilead.com</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 33%; text-align: left">March&#8239;7, 2022</TD><TD STYLE="text-align: right; width: 67%">Page&nbsp;2</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gilead has filed&nbsp;a current&nbsp;report on
Form&nbsp;8-K that includes this press release and some FAQs related to the information in this release.&nbsp;The information in this
press release should be read in conjunction with the FAQs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Trodelvy has not been approved by any regulatory agency for
the treatment of HR+/HER2- metastatic breast cancer. Its safety and efficacy have not been established for this indication. Trodelvy
has a Boxed Warning for severe or life-threatening neutropenia and severe diarrhea; please see below for additional Important Safety
Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><U>About the TROPiCS-02
Study</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The TROPiCS-02 study
is a global, multicenter, open-label, Phase 3 study, randomized 1:1 to evaluate Trodelvy versus physician&rsquo;s choice of chemotherapy
(eribulin, capecitabine, gemcitabine, or vinorelbine) in 543 patients with HR+/HER2- metastatic breast cancer who were previously treated
with endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy.&#8239;The primary endpoint is progression-free survival
per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by blinded independent central review for participants treated
with Trodelvy compared to those treated with chemotherapy. The trial targets a 30% reduction in the risk of disease progression or death
and is powered to detect a statistically significant difference of at least 0.9 months in median PFS. Secondary endpoints include overall
survival, duration of response, clinical benefit rate and overall response rate as well as assessment of safety and tolerability and
quality of life measures. More information about TROPiCS-02 is available at <U>https://clinicaltrials.gov/ct2/show/NCT03901339</U><FONT STYLE="color: #212529">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><U>About HR+/HER2-
Breast Cancer</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hormone receptor-positive/human epidermal growth
factor receptor 2-negative (HR+/HER2-) breast cancer is the most common type of breast cancer and accounts for approximately 70% of all
new cases, or&nbsp;nearly 400,000 diagnoses worldwide each year. Almost one in three cases of early-stage breast cancer eventually become
metastatic, and among patients with HR+/HER2- metastatic disease, the five-year relative survival rate is 30%. As patients with HR+/HER2-
metastatic breast cancer become resistant to endocrine-based therapy, their primary treatment option is limited to single-agent chemotherapy.
For patients treated with single-agent chemotherapy, the prognosis remains poor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>About Trodelvy</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trodelvy<SUP>&reg;</SUP> (sacituzumab govitecan-hziy)
is a first-in-class Trop-2 directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types,
including in more than 90% of breast and bladder cancers. Trodelvy is intentionally designed with a proprietary hydrolyzable linker attached
to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the
microenvironment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trodelvy is approved in more than 35 countries,
with multiple additional regulatory reviews underway worldwide, for the treatment of adult patients with unresectable locally advanced
or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic
disease. Trodelvy is also approved in the U.S. under the accelerated approval pathway for the treatment of adult patients with locally
advanced or metastatic urothelial cancer (UC) who have previously received a platinum-containing chemotherapy and either programmed death
receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trodelvy is also being developed for potential
investigational use in other TNBC and metastatic UC populations, as well as a range of tumor types where Trop-2 is highly expressed, including
hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, metastatic non-small
cell lung cancer (NSCLC), metastatic small cell lung cancer (SCLC), head and neck cancer, and endometrial cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-size: 10pt">Gilead Sciences,&nbsp;Inc. 333 Lakeside Drive Foster City, CA 94404 USA</FONT> <FONT STYLE="font-size: 10pt"><I><BR>
phone</I> 650 574 3000 <I>facsimile</I> 650 578 9264</FONT></TD>
    <TD STYLE="text-align: right; width: 50%"><FONT STYLE="font-size: 10pt">www.gilead.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 33%; text-align: left">March&#8239;7, 2022</TD><TD STYLE="text-align: right; width: 67%">Page&nbsp;3</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>U.S. Indication for Trodelvy</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, Trodelvy is indicated for
the treatment of:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior
systemic therapies, at least one of them for metastatic disease.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Adult patients with locally advanced or metastatic UC who have previously received a platinum-containing
chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. This indication is approved
under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent
upon verification and description of clinical benefit in a confirmatory trial.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><U>U.S. Important
Safety Information for Trodelvy</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>BOXED WARNING: NEUTROPENIA AND DIARRHEA</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Severe or life-threatening neutropenia may occur. Withhold Trodelvy for absolute neutrophil count below
1500/mm<SUP>3</SUP> or neutropenic fever. Monitor blood cell counts periodically during treatment. Consider G-CSF for secondary prophylaxis.
Initiate anti-infective treatment in patients with febrile neutropenia without delay.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Severe diarrhea may occur. Monitor patients with diarrhea and give fluid and electrolytes as needed.
Administer atropine, if not contraindicated, for early diarrhea of any severity. At the onset of late diarrhea, evaluate for infectious
causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold Trodelvy until resolved to &le;Grade 1 and
reduce subsequent doses.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CONTRAINDICATIONS</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Severe hypersensitivity reaction to Trodelvy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WARNINGS AND PRECAUTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neutropenia: </B>Severe, life-threatening,
or fatal neutropenia can occur and may require dose modification. Neutropenia occurred in 61% of patients treated with Trodelvy. Grade
3-4 neutropenia occurred in 47% of patients. Febrile neutropenia occurred in 7%. Withhold Trodelvy for absolute neutrophil count below
1500/mm<SUP>3</SUP> on Day 1 of any cycle or neutrophil count below 1000/mm<SUP>3</SUP> on Day 8 of any cycle. Withhold Trodelvy for neutropenic
fever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Diarrhea:</B> Diarrhea occurred in 65% of all
patients treated with Trodelvy. Grade 3-4 diarrhea occurred in 12% of patients. One patient had intestinal perforation following diarrhea.
Neutropenic colitis occurred in 0.5% of patients. Withhold Trodelvy for Grade 3-4 diarrhea and resume when resolved to &le;Grade 1. At
onset, evaluate for infectious causes and if negative, promptly initiate loperamide, 4 mg initially followed by 2 mg with every episode
of diarrhea for a maximum of 16 mg daily. Discontinue loperamide 12 hours after diarrhea resolves. Additional supportive measures (e.g.,
fluid and electrolyte substitution) may also be employed as clinically indicated. Patients who exhibit an excessive cholinergic response
to treatment can receive appropriate premedication (e.g., atropine) for subsequent treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Hypersensitivity and Infusion-Related Reactions:
</B>Serious hypersensitivity reactions including life-threatening anaphylactic reactions have occurred with Trodelvy. Severe signs and
symptoms included cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis, and skin reactions. Hypersensitivity reactions
within 24 hours of dosing occurred in 37% of patients. Grade 3-4 hypersensitivity occurred in 2% of patients. The incidence of hypersensitivity
reactions leading to permanent discontinuation of Trodelvy was 0.3%. The incidence of anaphylactic reactions was 0.3%. Pre-infusion medication
is recommended<I>. </I>Observe patients closely for hypersensitivity and infusion-related reactions during each infusion and for at least
30 minutes after completion of each infusion. Medication to treat such reactions, as well as emergency equipment, should be available
for immediate use. Permanently discontinue Trodelvy for Grade 4 infusion-related reactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-size: 10pt">Gilead Sciences,&nbsp;Inc. 333 Lakeside Drive Foster City, CA 94404 USA</FONT> <FONT STYLE="font-size: 10pt"><I><BR>
phone</I> 650 574 3000 <I>facsimile</I> 650 578 9264</FONT></TD>
    <TD STYLE="text-align: right; width: 50%"><FONT STYLE="font-size: 10pt">www.gilead.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 33%; text-align: left">March&#8239;7, 2022</TD><TD STYLE="text-align: right; width: 67%">Page&nbsp;4</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Nausea and Vomiting:</B> Nausea occurred in
66% of all patients treated with Trodelvy and Grade 3 nausea occurred in 4% of these patients. Vomiting occurred in 39% of patients and
Grade 3-4 vomiting occurred in 3% of these patients. Premedicate with a two or three drug combination regimen (e.g., dexamethasone with
either a 5-HT3 receptor antagonist or an NK1 receptor antagonist as well as other drugs as indicated) for prevention of chemotherapy-induced
nausea and vomiting (CINV). Withhold Trodelvy doses for Grade 3 nausea or Grade 3-4 vomiting and resume with additional supportive measures
when resolved to Grade &le;1. Additional antiemetics and other supportive measures may also be employed as clinically indicated. All patients
should be given take-home medications with clear instructions for prevention and treatment of nausea and vomiting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Increased Risk of Adverse Reactions in Patients
with Reduced UGT1A1 Activity: </B>Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are
at increased risk for neutropenia, febrile neutropenia, and anemia and may be at increased risk for other adverse reactions with Trodelvy.
The incidence of Grade 3-4 neutropenia was 67% in patients homozygous for the UGT1A1*28, 46% in patients heterozygous for the UGT1A1*28
allele and 46% in patients homozygous for the wild-type allele. The incidence of Grade 3-4 anemia was 25% in patients homozygous for the
UGT1A1*28 allele, 10% in patients heterozygous for the UGT1A1*28 allele, and 11% in patients homozygous for the wild-type allele. Closely
monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue Trodelvy based on clinical
assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually
severe adverse reactions, which may indicate reduced UGT1A1 function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Embryo-Fetal Toxicity:</B> Based on its mechanism
of action, Trodelvy can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. Trodelvy contains a
genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential
risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Trodelvy and for 6 months
after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment
with Trodelvy and for 3 months after the last dose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ADVERSE REACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><BR>
In the ASCENT study (IMMU-132-05)</B>, the most common adverse reactions (incidence &ge;25%) were fatigue, neutropenia, diarrhea, nausea,
alopecia, anemia, constipation, vomiting, abdominal pain, and decreased appetite. The most frequent serious adverse reactions (SAR) (&gt;1%)
were neutropenia (7%), diarrhea (4%), and pneumonia (3%). SAR were reported in 27% of patients, and 5% discontinued therapy due to adverse
reactions. The most common Grade 3-4 lab abnormalities (incidence &ge;25%) in the ASCENT study were reduced neutrophils, leukocytes, and
lymphocytes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>In the TROPHY study (IMMU-132-06)</B>, the
most common adverse reactions (incidence &ge;25%) were diarrhea, fatigue, neutropenia, nausea, any infection, alopecia, anemia, decreased
appetite, constipation, vomiting, abdominal pain, and rash. The most frequent serious adverse reactions (SAR) (&ge;5%) were infection
(18%), neutropenia (12%, including febrile neutropenia in 10%), acute kidney injury (6%), urinary tract infection (6%), and sepsis or
bacteremia (5%). SAR were reported in 44% of patients, and 10% discontinued due to adverse reactions. The most common Grade 3-4 lab abnormalities
(incidence &ge;25%) in the TROPHY study were reduced neutrophils, leukocytes, and lymphocytes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-size: 10pt">Gilead Sciences,&nbsp;Inc. 333 Lakeside Drive Foster City, CA 94404 USA</FONT> <FONT STYLE="font-size: 10pt"><I><BR>
phone</I> 650 574 3000 <I>facsimile</I> 650 578 9264</FONT></TD>
    <TD STYLE="text-align: right; width: 50%"><FONT STYLE="font-size: 10pt">www.gilead.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 33%; text-align: left">March&#8239;7, 2022</TD><TD STYLE="text-align: right; width: 67%">Page&nbsp;5</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>DRUG INTERACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>UGT1A1 Inhibitors:</B> Concomitant administration
of Trodelvy with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to
SN-38. Avoid administering UGT1A1 inhibitors with Trodelvy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>UGT1A1 Inducers</B>: Exposure to
SN-38 may be substantially reduced in patients concomitantly receiving UGT1A1 enzyme inducers. Avoid administering UGT1A1 inducers
with Trodelvy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Please see full <U>Prescribing Information</U>, including BOXED
WARNING.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>About Gilead Sciences</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Gilead Sciences,&nbsp;Inc.
is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating
a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases,
including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Forward-Looking Statements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release includes forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors,
including Gilead&rsquo;s ability to initiate, progress or complete clinical trials involving Trodelvy within currently anticipated timelines
or at all; the possibility of unfavorable results from ongoing or additional clinical trials involving Trodelvy; Gilead&rsquo;s ability
to submit regulatory applications for new or expanded indications for Trodelvy, including for the treatment of metastatic HR+/HER2- breast
cancer, in the currently anticipated timelines or at all; Gilead&rsquo;s ability to receive regulatory approvals in a timely manner or
at all, including regulatory approvals of Trodelvy for the treatment of metastatic HR+/HER2- breast cancer and other indications, and
the risk that any such approvals may be subject to significant limitations on use; the possibility that Gilead may make a strategic decision
to discontinue development of Trodelvy for the treatment of metastatic HR+/HER2- breast cancer and as a result, Trodelvy may never be
commercialized for this indication; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other
factors are described in detail in Gilead&rsquo;s Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2021, as filed
with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially
from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that
could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and is cautioned not to place undue reliance on these forward-looking statements. All
forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any
intent to update any such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>U.S. Prescribing Information
for Trodelvy including <B>BOXED WARNING</B>, is available at <U></U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I><U>www.gilead.com</U>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>Trodelvy, Gilead and
the Gilead logo are trademarks of</I>&nbsp;<I>Gilead Sciences,&nbsp;Inc., or its related companies.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>For more information
about Gilead, please visit the company&rsquo;s website at <U>www.gilead.com</U>, follow Gilead<BR>
 on Twitter (@GileadSciences) or call Gilead
Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-size: 10pt">Gilead Sciences,&nbsp;Inc. 333 Lakeside Drive Foster City, CA 94404 USA</FONT> <FONT STYLE="font-size: 10pt"><I><BR>
phone</I> 650 574 3000 <I>facsimile</I> 650 578 9264</FONT></TD>
    <TD STYLE="text-align: right; width: 50%"><FONT STYLE="font-size: 10pt">www.gilead.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>tm228518d1_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Gilead TROPiCS-02 Readout Announcement &ndash;
FAQ</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">7 March&nbsp;2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B><U>Q1.</U></B></TD><TD><B><U>Did PFS meet your bar for clinically meaningful?</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>There is a broad range of views on what is &ldquo;clinically meaningful&rdquo; in this population. We are evaluating the data and
will explore potential pathways with regulatory authorities to bring Trodelvy to this group of patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B><U>Q2.</U></B></TD><TD><B><U>You reference TROPiCS-02 clinical activity consistent with the Phase 1/2 IMMU-132-01 study. What were the results of that study?</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>The Phase 1/2 IMMU-132-01 study evaluated Trodelvy in a subset
                                            of HR+/HER2- metastatic breast cancer patients. As published here [at <U>https://www.annalsofoncology.org/article/S0923-7534(20)42445-7/fulltext</U>]
                                            (Kalinsky et al, 2020), a PFS of 5.5 months was reported. There was no comparator arm in
                                            this study.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B><U>Q3.</U></B></TD><TD><B><U>What does this mean for HR+/HER2- earlier line patients?</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We saw statistically significant clinical activity in TROPiCS-02, and there
is no change to our plan to move forward with studies for earlier line patients.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B><U>Q4.</U></B></TD><TD><B><U>What are the next milestones for this trial?</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The final overall survival data readout is expected in 2024, subject to the
timing of events.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The study allows for a second, interim OS analysis and we will update you
on our expectations following review with regulatory authorities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">In the meantime</FONT>, patients will continue to be followed and treated
per protocol.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B><U>Q5.</U></B></TD><TD><B><U>Is it reasonable to expect a statistically significant final overall survival readout given the data so far?</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>In the first interim analysis, the study demonstrated a trend in improvement for overall survival which means Trodelvy is showing
a numerical improvement that was not statistically significant at the first interim analysis. We will continue to follow patients while
the data matures to understand the final overall survival result.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B><U>Q6.</U></B></TD><TD><B><U>How does this impact Gilead&rsquo;s 2022 guidance?</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>We are not changing our 2022 guidance at this time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>In terms of the 2022 revenue guidance issued on February&nbsp;1<SUP>st</SUP>, we did not assume any TROPiCS-02-related launches until
late 2022 at the earliest.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>We expect an immaterial impact to Operating Expenses in 2022 with the trial still ongoing and our planned studies on-track.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>We are evaluating the impact to our in-process R&amp;D on the balance sheet, and that could impact our GAAP EPS guidance. We expect
to update you on our Q1 call.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B><U>Q7.</U></B></TD><TD><B><U>Is there any change to your goal that 1/3 of Gilead&rsquo;s revenue will derive from oncology products in 2030?</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>We remain confident in that goal.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>The 2030 goal was risk-adjusted and &ndash; given the nature of our business &ndash; allowed for a range of outcomes across our portfolio.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B><U>Q8.</U></B></TD><TD><B><U>Are there any changes to the Trodelvy program?</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>We are very confident in Trodelvy&rsquo;s activity and pan-tumor potential given ASCENT trial data for mTNBC and TROPHY U-01 for mUC
 &ndash; and the approvals that followed &ndash; in addition to TROPiCS-02 which showed statistically significant PFS.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>TROPiCS-02 is ongoing, in addition to a range of other Trodelvy trials, including 1L TNBC and NSCLC in combination with Keytruda,
or in our other ongoing later-line trials in bladder cancer and NSCLC. Most of the 20+ oncology trials we plan to initiate this year include
Trodelvy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Forward-Looking Statements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This FAQ includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead&rsquo;s
ability to initiate, progress or complete clinical trials involving Trodelvy within currently anticipated timelines or at all; the possibility
of unfavorable results from ongoing or additional clinical trials involving Trodelvy; Gilead&rsquo;s ability to submit regulatory applications
for new or expanded indications for Trodelvy, including for the treatment of metastatic HR+/HER2- breast cancer, in the currently anticipated
timelines or at all; Gilead&rsquo;s ability to receive regulatory approvals in a timely manner or at all, including regulatory approvals
of Trodelvy for the treatment of metastatic HR+/HER2- breast cancer and other indications, and the risk that any such approvals may be
subject to significant limitations on use; the possibility that Gilead may make a strategic decision to discontinue development of Trodelvy
for the treatment of metastatic HR+/HER2- breast cancer and as a result, Trodelvy may never be commercialized for this indication; and
any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead&rsquo;s
Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2021, as filed with the U.S. Securities and Exchange Commission.
These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking
statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The
reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties,
and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information
currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>gild-20220307.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWayN2bOdzZR+2YkxtmB1bVlqHyEvdtpOsS3yXjKWkdcC -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:GILD="http://gilead.com/20220307" elementFormDefault="qualified" targetNamespace="http://gilead.com/20220307">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://gilead.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="gild-20220307_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="gild-20220307_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>gild-20220307_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>gild-20220307_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gilead.com/role/Cover" xlink:href="gild-20220307.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://gilead.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm228518d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm228518d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  S +X# 2(  A$! Q$!_\0
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M-#966Z-[2OHG]@;XI_&3X@>*/&5OJ_QFM_CEX&B\!>#M;UF7Q:NN1>+/A_\
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M--FM=:US0?#GC+QEKN@:=J<UGJFH6-I>6^FI-I-A>3V.D-8VCF&OT@C^XOT
M_+I^5%% %:\1)%02(CA&$R;T5MDL4D9CE3<#LDC))1UPR'E2#S3)((3<12-&
MK2('6.5QOEA$SI%,()'W/!YJ*HE\ID\P@,^Y@#110 CJL+321(J22%!)(%7S
M90FQ$\V3&^0HA*H79BJG"D"FW$<5RJQ7,45Q$SJYBGBCFBWQ7 :)_+D5D#QL
MBLC!0RNH=2&&:** +(=_,<;C@/"H''1TW-^9[GD= 0.*CC@AB,ABB2+S)&ED
;$2B)9)92S2S2+'M5YI"H+RL#(V.6-%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139684272021080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 07, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  07,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GILEAD SCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3047598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333
Lakeside Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">574-3000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value, $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GILD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>tm228518d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gild-20220307.xsd" xlink:type="simple"/>
    <context id="From2022-03-07to2022-03-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-03-07to2022-03-07">0000882095</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-03-07to2022-03-07">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-03-07to2022-03-07">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-03-07to2022-03-07">2022-03-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-03-07to2022-03-07">GILEAD SCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-03-07to2022-03-07">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-03-07to2022-03-07">0-19731</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-03-07to2022-03-07">94-3047598</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-03-07to2022-03-07">333 Lakeside Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-03-07to2022-03-07">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-03-07to2022-03-07">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-03-07to2022-03-07">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-03-07to2022-03-07">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-03-07to2022-03-07">574-3000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-03-07to2022-03-07">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-03-07to2022-03-07">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-03-07to2022-03-07">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-03-07to2022-03-07">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-03-07to2022-03-07">Common Stock, par value, $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-03-07to2022-03-07">GILD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-03-07to2022-03-07">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-03-07to2022-03-07">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M&U#<\0=G6WUR3&Q7EE*^V,8LOG4\2\02%ADK0>'GE8U9DE@EX/AV%'7*9]K
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #20V=4JL0B%C,!   B @  #P
M 'AL+W=O<FMB;V]K+GAM;(U1T6[", S\E2H?L!:T(0U17D#;D*8-C8GWT+K4
M(HDKQX6-KY_;JAK27O:4W-FZW%T6%^+3@>B4?'D78FYJD6:>IK&HP=MX1PT$
MG53$WHI"/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7<P
M.6/$ SJ4[]ST=P<F\1C0XQ7*W&0FB35=7HCQ2D&LVQ5,SN5F,@SVP(+%'WK7
MF?RTA]@S8@\?5HWD9I:I8(4<I=_H]:UZ/(,N#Z@5>D(GP&LK\,S4-AB.G8RF
M2&]B]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&[O+H YMR
MR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7
MLN48<?R>Y0]02P,$%     @ TD-G5"0>FZ*M    ^ $  !H   !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C
M$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C
M,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI
M160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%
MKLWC":[?#'!X=/X!4$L#!!0    ( -)#9U1ED'F2&0$  ,\#   3    6T-O
M;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^
MDV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT
M(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"
MS&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE
M8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F
M"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D<WC_0QI-^2!8ECF
MS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ TD-G5 =!
M36*!    L0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q0
M2P$"% ,4    " #20V=4;-(W(>T    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #20V=4F5R<(Q &  "<)P
M$P              @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( -)#9U34^/'.-00  #$0   8              " @0P(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #20V=4GZ ;\+$"  #B#
M#0              @ %W#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( -)#
M9U27BKL<P    !,"   +              "  5,/  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( -)#9U2JQ"(6,P$  "("   /              "  3P0  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #20V=4)!Z;HJT   #X 0  &@
M            @ &<$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " #20V=499!YDAD!  #/ P  $P              @ &!$@  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #+$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>122</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm228518d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gilead.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm228518d1_8k.htm">tm228518d1_8k.htm</File>
    <File>gild-20220307.xsd</File>
    <File>gild-20220307_lab.xml</File>
    <File>gild-20220307_pre.xml</File>
    <File>tm228518d1_ex99-1.htm</File>
    <File>tm228518d1_ex99-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm228518d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm228518d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gild-20220307_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gild-20220307_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "gild-20220307.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 122,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "GILD",
   "nsuri": "http://gilead.com/20220307",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm228518d1_8k.htm",
      "contextRef": "From2022-03-07to2022-03-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://gilead.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm228518d1_8k.htm",
      "contextRef": "From2022-03-07to2022-03-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-22-030888-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-030888-xbrl.zip
M4$L#!!0    ( -)#9U0Y!"RW.P,  .\+   1    9VEL9"TR,#(R,#,P-RYX
M<V2U5MMRVC 0?6YG^@^J7SORC:9I""23DB9E2I(.-)?FI2-L0=3(DB/)7/KU
ME7P! L8%TO(D[9YS=E?:E6D<3R(*1EA(PEG3\FS7 I@%/"1LV+2N>_"DUVJW
M+7!\].8UT+_&6PC!&<$TK(-3'L V&_!#<(DB7 ?GF&&!%!>'X ;1Q%CX&:%8
M@!:/8HH5UHXL4AWLV9[?!Q!NH'N#6<C%=;<]TWU0*I9UQQF/QS;C(S3FXE':
M 8\V$^PII!(Y4W,G;O[;C'Y!9# COT,G>^/]29?<#3'[F'10[3ZX1=-+OW\5
M_K[OOO-_/$Y4],GKW]"G+]//HU#%5[)7F][]^GK[& :M+&1#!@\X0D!?!I--
MR]27ES>NV5P,'=]U/>?NHM-+<58&K$\H88]E<._@X,!)O05T!3GI"UI(UQSC
M[B.)9\K:2RKPA$F%6/ ,'ZH981&\YV3.9U!2"OV004D!#?$23N+ 'O*1HQT:
M[WM/[PMH(N$0H7@&'R#93V5S1PJ'K@=K7D&10JW"M;$<"M4TQK*4D+E*:.?M
MSNF,,=2C@$+3I0;INS5W7\\:Q1%FZHR+Z!0/4$)U2D\)HF1 <&@!A<00*]-V
M,D8!KM0J.A<QQG6#ZRG++<86QT1WL#:\:IBKK@M.\7>=-3 +/5IERL;EM+A^
M'"Q PJ:5+8V&5DQ50CP@C*2A\@GR #3SDIBB]#*E-)QE\()$(G%XQ8[2=2RP
MU+PT]XXVY,0<LH84(!HD=#O./)522FXHSFA^:L64=/$ I--5-S??M"0Q[YN5
MVQX$'C0M?9 A+"[GIR[-UCU10(QTQ72E)[]\&GG@0@*)8$5E9?JU"(^Q4$2W
MY\*(9ZD39>C?%L( $T=:P/D7)5/4W[9D3<'T/];:,?J+1>;CX<SG(]\OSU!#
ME\N% FQE%*O>QNQ5[_ @E:J@F!TL>-"8H.?KA\2>R'">Z39)S$]@NR0*W@Y)
MK'VARS*0ZPEF";/EIJ$K7_O*\*5,!U,E"PN<:^V2SNJWX07YI&([)/3LLD,E
M'"-DI%VCXU<D]3=FNI<[M4C $Z;$-*UPPR99I!2;]#BVOIGE[_QFEU*PL@LQ
MG_X7-$?Y/X==$UG?&@TGT]3+/U!+ P04    " #20V=4+^*J8/\*  !LAP
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M,S W7W!R92YX;6S-G$USVS80AN^=Z7]@U;,^G3:U8C=C*U9&$R=V+25I>\E
M)"1A# (J %K2OR] BHH^"'!]R=H'6R87P+[/0B"7 'CQ=IWRZ(DJS:2X;'1;
MG49$12P3)N:7C<_CYM5X,!HU(FV(2 B7@EXVA&R\_?/GGR+[<_%+LQD-&>5)
M/WHGX^9(S.2;Z!-):3]Z3P55Q$CU)OI">.:.R"'C5$4#F2XY-=2>*!KN1[^U
MNKUIU&P"ZOU"12+5YX?1KMZ%,4O=;[=7JU5+R">RDNI1MV*9PBH<&V(RO:NM
ML^YL?XKB%YR)Q[[[-26:1I:7T/VU9I<-U^ZVV=592ZIYN]?I=-M_?[P=QPN:
MDB83CEM,&V4I5TM5N>[Y^7D[/UN:GEBNIXJ7;9RU2W=V-=NS+&"_YXEF?9V[
M=RMC8O*PUS83>2W<?\W2K.D.-;N]YEFWM=9)HX2?$U22TP<ZB]Q?&[U=JW/;
M)TCBPM5VI]H#:;NC]3,OM%!T=MFP)HFMN]?KG'5>NYI_/3 RFZ7MEIJY7M6(
MV@>M+A755)A<Z*T]<%"$KHWM3#0I*W+MP_PRS#C3;4?I1DW7J[+4MF0_%I9;
M-TI'N(P/VN:.OCP26O;DG+&F<6LNG]H)999UK_O?*_>Q67S,*=A_O^6-74VU
M420V96V<3"G/V_AF;8Y,VC_(LY+(Q-9:[=BAQ;%?^Z&[4G$D54*595[6151\
M$+#3SKFU:"^)LA4UXX7M1V7IF9*IC]"6AO0XN@_+-O'CB%Y9'Q+GQY"3>372
M(Q,@TRX&U$HUF%3?41TKMG1L:N >6 (9]U 95VA#0%U^CQ[HG#F?G3ON\DO=
MP? 8X2D"A'^&.6H$U2)&X4J(C/ 'NI2J!OZA)9#Y*TSF5=H04?^5$66HXAL(
M[1-C(/#?,(%[%"(RGR@B-'.,(-!/K8'4?T>](?%H1,0^7E#.78I'!*BW5]D#
MT;_&1._7^4+@WSRYZ[Z]W,#Y[Q4!AN"/EQ*"$[6(4;BGBLG$7NH5@/^),9#\
M.29YCT)TYC<B@1+?F8)S)'S@1_(0<0^9C@DOO!K:8SJ,O,(<BATE-ZV5B8[^
M'TH4&/R>,10[2KI:(Q$!^B!3ZL"AX CCMX9B1TE4ZT0B<+\1AIF-FR_XE*73
M[P]>#WF?6D$YHR2G/E%H?,LG$\*XJ9 0XV-+*&>4G#0D#HWUP&I2A(]$0M<?
MZ"8$^\042ALE%PW*0\-]KUA*U&;,XOH!Y-06"APE PT+1",^(>M18I6Q&2LF
M%NO!>XM ^:.DGR"Y:&$8B5BJI=Q[W#R0F?UN;@8R"0[Q-06A(4')2Y\A'2TP
M5TEBD>GMGULF:#<4CDIS\%P37A ",E\0^M[ST/?@Z%'RU5J9+PC]V?/0G\'1
MH^2LM3*QT0_LQSLUD2O/K+;7&(H=)6>MD8@-/;_ZW*E[)9]8L>ZJCOQ)"2A^
MQ%0V+!8[!MN+/Z37EY90YHAI;;4X;-;W4AO"_V7+NKO,:GLH=\0$-R04X\%D
M$7_WD,.W7.G(!,H8):>ME(.!U45:4>+OQH<64*@HB6J5& 2FM]+-H2RD"#[+
M/;6"LD7).'VB, 9BMXQ9>X>!O=/@U7(HP^RQ# 247Q4SUHN!3--,;)_K>&;8
M/*90Q"AI8E > NZQY"QFAHGY1WL'J1CAU:RK[*"@49)"OS $RO>*NHA3>VN>
MKQES>Q[4W6SF&XE#]E#J*#EAO5!\^B.M,ZJ>&X.*4M!(H*2'4-$88PZ-,SL,
M;KJ]Z<3MXO&,."=64-XHJ:%/% +?3W*BB-L_.-ZD4\G]6U4J#:&441+!@#0$
MT >^5",^,H'"1<D *^4@C@\WZWA!Q)SZ5T946T(AHV2$(7&H8_$<-!;/GSD6
MHV2&/E&(?(OUZ?;;=3?E;$[\.]R"!<#[?C"I!Z1B["W,MR&YW>8JS7T9V@_5
MZ#VF4.@X6SA#\C!P9PDS-"G<&C)!1&Q3K]V>.T\F7U\*&@2</9Y T6A3!%\I
MYQ^$7(DQ)5H*FA3I0&B6P%L$&@G$.<D:N6AA^")Y9DFI? &J\GP7/*90[(AS
MD1YY>.L]BT75N^M1\9J1$'5?"2A\Q$G)L%C$M7"&.K_9$WU'#-EZ&8J!KP0T
M!H@3E&&QJ&OXU<!>C.8R/!=_9 @ECK@$MU(:&NAQ2CB_SC035 ?'F2-#*&C$
MM;:5TM! WZ14S>T@]U[)E5EL]Y^&@'L*0,$CKJ@-2L4+P/K[OO=B;UZ0?H4U
M^(T*B.B](C%?&1+';J%&<847"5$>\B%[*'O4C9]^H0CT[\R"JOU[J]RAD<WO
M0@LJZDM!(X&2UD)%XUUO]]X^$+S<'MA!F2,FL%7"\/9Q95/.XB&7)'C??F &
M98R8K5;(0D-\3<2CRI8FWMPK&5/JIF'T[IL'2)J %4##@IC'/@L%WJ,%F:9N
M@Y.,'\<+*US?929_0ZOU,?B (5@.&A[,3:8 X8AW1_K[!C2:7&\>Z(PJMP1B
M0M?FVC;V&+Y9 A2'Q@CUS4A@#!6ANFB?Z+JU!]Q[>(LS[I=[UZP]\C]02P,$
M%     @ TD-G5.0@XDN:$P  WVP  !$   !T;3(R.#4Q.&0Q7SAK+FAT;>T]
M:U?B3-+?/<?_T"^[SQ[GK(%P$T&'/0CH,"HBX&7FBZ=)&N@Q)#'I"/CKW^I.
M @$2O 7'9W:?BT*ZNZJZ;EU5W1T/_S,9:>B16#8U]*^)=%).(*(KADKUP=>$
MP_K2?N(_Y>VMPR&#?M!7M[\FAHR9I51J/!XGQ]FD80U2Z6*QF)KP/@FW4VD2
MVB\CR^G4[?E91QF2$9:H;C.L*V0V2*/Z?31\WCKKVK,TNM"5/_&19%,KH*%5
MG0\(=MY+N8T+75EHU[S;E?E=J6WD,NG".CK<'K,!DZB^:4XSS)#<'K7/YMU9
M>/]YUQ2SL&[W#6N$&<B00\I+<D;*[ 6 2#91%@#!]^3 >'P6SKZ43?MP5H2S
M.%/>W,/VC.,J66*WCQ,:8$0F_9#SNUJD'PEX+P6M?D?'E@88F[/.?6SW1$>O
M0<"5Y'2 :FBQ#(W8H6-$2\@@Q7!T9DW#Z?<:Q3!_@&VQ503P, 3V2>.L-NL[
MH!K!:E(Q1KQG1L[*A80P-W@*OQ'_YY!1II'R8<K]#:TCPC#B$"3RX-#'KXFJ
MH3.B,ZD[-8'_BOOM:X*1"4NY5IGBXU(>V,/_DR1T3(FFEE"'L /4Q"-20A-U
M<H :-?'A3LY4[JXZ?V5J)Y5*"W[QB2!)>NGH;.V.3_1N/L$[?X*O@)++S$:]
M97B^>$= VX!Z^*^N _^F56",A;6&KI+)*9G>R?#/_GY&+N;?"K<R(KH*_[-C
M#0_N^EBSR2M [1T!EVMWZ3O/4;@PX=%K8&3N.D-L$?LN<R?\H@O$%L]> Z?&
M:6EYL+(K)$4"[QGJ%-ELJI&OB3XH7PFE99.A+AU!ER89H[8QPOJN^V 7"+!H
M7ZBY2A_]<2JU30U/2T@W="(:Z:3$]958W!#$-ZJJ1!=FP;]"QZ8S EB*J_$3
MUN9^Y-@R1EQ7)#DKR05FS#\GD ZS!E2$ED*U(5&>J\-A:@'%>["Z3O5K AQQ
MJ6> R\&Z4),@/0M:E"B+]E 24@N,X!2!?R06+-K$=GMP1URRQ0H+I"&Q;):&
MPL>"-:J2;TC)B:TFO&8&CN-KPJ8C4R.NL_!0+0)WT=F&8_G8H)O0BI+'#$35
MM<SPG9H_C @YS)[.GE.5M_0IL9"8"@E=OJJ-TT69+0^>HTN%XO.PF<!?0UVE
M F((B]4P(^7Y%'Q(\[:582#*B$%^RS)9"P3X#SV6+O+9T:G+9##(%6Z."+8=
MBY0]RRU!'Q^8W[2(@D.+@.^Z@4@4'A-$IS?CF+N;%3S@&D",J[SE8X5!8&98
M@>;7\V"9QC"H :0UHALCJC^']GF^+.,- ^RW+W!AA:&>A0;LT74/OM<\3,%X
M^,W_/31?ZZ$/T A; ZJ7$.\J)\K_^D=Z3SXX3)GEF #.0 56I[:C$:F%!V(1
M#2X0[EB)&2:,]T%)/8,Q8R2>C*G*AIP.^:_$PLB>80$_W)%'&E;N40;PVX9&
MU0/D-?IPW/;TO)U/3K+I$ZR6\'3.!,Y9[V> ^M0"^1_"]YZAJ2B]_SJHA60N
MSX&+C_#I '%/(V&-#J"' EZ26,#$7OFJV>C6:ZC3K73KG<-4KQPI_G=1L(Z$
M3KUZU6YT&_4.JC1KJ'Y;_59IGM2WMZH7Y^>-3J=QT5Q+V"L9'B LD]Q;0]<-
MMH>0)C,#P-62U23*R/E<,4Y2-F)SG+S>6TP/0"#L,&-F:9G\LX;VN0P)YNYC
MC1;29NWI^*)]C@YM$^MB >1Q=U&NBW1"DFJ&XO 8D*=Q=\HL\YGG0$]4_KYO
M6(UN\5H%<.\-@H/X$N5]Z70YXCQ,<4K+'Z33[U\=/HV*;M2*7ZQLX#?;]687
MM>NMBW8W3BFF"WO)M$<#_YR-(,-[1G4>D9>0)"?E/.<L$-=R+-O!.MO>8@:@
M4'C5":6SR+!0.K^C?D%&_[!GN;E(=TAX%\>BC *)]8DRQ#KPO:(PZ(;2Q6PN
M9AU]D:O8C.!JL-2BBV-/:FC'_UZOM,]@$>QN;]6OYU*MU[Z4$'?J2SYE?\FG
MM$2&47?SCW#GDCXFDWSQZ?:DM_]FYQ+,=57 -()Q0Q5/IP0"8CW,^2P0EBB?
M8TL9HL(NXE!_KS_ZR+CVTWBNSQ>E1KJW994O>"KOUG;:9$!M7M1FO-85KO'6
MC7PZ.>D:72<=PW(:AC=1/FF<U2L005<;]6:UWME%C68U^0&*O>!L(N/8G?H$
M@Q/ED^">U)H1O[V%;62;1.%U%!518#2S$?A="\9]V9SU_3>9S.:XR'!/(R!D
M30.]4L1FGIP0WTVLJO[W5R,-I-BSS%DQ- V;-K#1_R2JM\SRP3\2BU$%:[[J
M@3C\:L\A4_U>'NAL]J\(>Q?&_NHB\YJ5T377AJX8EFE88M>KPV -JKK[.U5#
MC? :+4J->YW(F6HOCG62;\[Q:B(CIF4\<DM<7"A?0"<$#43#8UABUSH6[R-3
MH]F?VSC[:POL/Z8: 5I[Q(K@M=4W;UJR^EW9B\U#SW$FRK*4+A:RZ?>R;?-:
M>[S MBZ>-+PBMR(T8AT/\UGK\NI>OJ2YM\=URSR,("!1+N:DK)PKY(O[+^0I
M_+#>XC!B9/>.L">>>5RP(;'0=T@T;)6*E,3/06!Q7##!+VOU(D[BJL9H1&U^
M0 -QS45-(_EQR!OM#JJ/3,V8$LMGQ:+@5^CQ!9H2BU#YPX++-\5'Z\QV;GQ'
M"\97456+V+;WZXSJ)!UN>/CQ"D]NCW.%CN;:=#RV%X(_4<YFL]M;9_B>V%0E
MJ&;1QY"U8&YYO?+N2AE*#IME%3Y>6%UCK(?/L7%V,^[7G(%N:K$YEQ74B?*Q
M88-D$'^TSJ^$32L3-BUA\1=6"U9<JBL1"WVQ>7]=D(\N]VXS'[?0AQ.8*%=!
M1P&83O%')P^19K+CT<HSAY8%9%(3:Z@^(8K#0/^VMR[ZX"6('9DNQ&^X+Z_P
MQHOU14K7 B7&VD]J1L>6@^L38R!;][E</VYS6L#.%^J<G/LP58I0(* &<7)B
M2RC78?OH1615*_QUA+NQBD5PM!Y85YVG^WKG]K@PC$$/@O@2Y;V\'"%W*6I)
M.#,@'FL-#7UML/Y#U0UEKZ+4?L5 \S+*1#E?X+&E'$7\YOQ?M/[.BSW_^L=^
M)ETXL%&7:,3D9&]ON83O\L!1<WC6C;@0XE7X_^VG?(@E-PV&*J:I0= +0>WO
M4+5C""0@ FJ*2IV%O*^>;]_=WJ)]5!6[(BKJ\(@!G6&;H3:!A(5]A+:]%J!W
MDH//=_DL!]>5ZI" ,D$ZAK )X9)I49ZB]8P)ZA'-&".8+F_D;$#[TNGV5I]J
MW,*HC2@__JH"'YB!;#IR-(9U8CBV-D4VI"QV?RJ&>@.,'C#:S60,%^:\"(H<
M@&,AK$_]MKZA 78^CL=PE&=E=BDN[F:3!5\5\LE\T&+>#C^H2[\<&_*VZ0LE
M@%9R1JF/1U2;EM -,(#[,SLDL8SN-%]6*MZR<F-1!K+B&:ZC>_FD';ZV7!8,
MO$].)DVU$,OF5-1!S%"27$'L'T2N/,%?R ,!9 5A(-/;\.1JR5T=RF7RGH*Q
MQ?U-OJVYDRZ@ZG$;9;)R$CK.+/B/TH.LIP<=6"\4F+L^. <K!U/7PI7@R;B^
M/=9->V1N5@E6Z7F=!LS' T== *OB3^>PE,X$-&!A6WLF_YR<='O^F2J0\U2@
M91%N<_RHL3B2PCVX!?EC5*QYE1]?W[2K]@B_/=A\B2I$T_4ZE0 XDA( ]*QW
M2.=4*;/3^_(R!7'[_IDJLA>N(@W;=HCUK**TR,WUC\>6,?T5SZF&%RK*"G6;
M5I<LD7([RLO4Q>O[;G59" WCC5NBE,ZB@R$+/0',\08643>*(Q;$@4%FS4X:
M"=LR^MM;G%7 H=BBN#]A-W;I5'1O.;-;AN)VG)&4S<2['];E-]]X"%['RA!5
M-6SSH/OY?;EE,C32#RAGV,#/-G$+B[I!9SJ"K';'7K_QL[%9>VHJ<4B@Y,E,
MGNH;FW/3.XLB9#WS86"R-T.J#/U-J/;,O#_99N*:$P>>=YJF,SVAT>$+UB3_
MX^A8'SQ.;V@,9;1EG)!9PTH"W.PP0[G?!=%:Z!%K#ME%_Y23LIQ&)K]S-7S'
M68+7Z=YF6>_'#IXAN784SG>S^FU\-FW?7#Z2&/B^@%"< JM]##_#;76S7):7
M%-RWVC4G[^JUG]=7M]\4]O:3=\M;:P2PKNZJA=$$CA46_2:V5?R 3C2C!_E9
MAV@0&J!S;-T3]LJS"^_:ZEX6[PL#[GA+0Z] W-!5'H82U)LB153IH-<]&@^)
M.#RQ5$&C-@)5@1B6 QJ@@66,V7!["\)9DY?5L(U4TJ>Z>\201[+NO')RWB^Y
M+15&W//>6;3#.Q8.1'W$[TS%"463GU#D-=(Y./!^4F85X/96V%'R&6@>*L\'
M!H G?P/;/ZCNNIJA>05\T5KWY+B]Y0H2^7+<7/977=A)]0DX$>BK+O9P%V.H
M8_M!;M C]O:MU)<D?FL(>U7.-_NU80E_D"(U^B&&[^O++EC[DA?9WA)NA*[4
MX(?@(X1O!A^A&R*)<VPB>H$(O4H_?WD)%8F=>Y6:2TX@TZ8<^Y@";JZG.LP)
M6BSR2&T8!YX'ZPHOSV%%O-=#Z#9_=8R*+=5VB_QJ5 J9W<%??*<2="3)&,W!
M5Z!X562#*7L(Z-]VSS>0PH3>\PW< _[MQ\%_HRSX/ Y@Y(/#RTV P)V4""Q?
MRM^@V-*9$*>P)["'[>BZ1/F7U5>P6@3?2ST"!@VDF8+4(+*]$%R<@$AD<^8N
MH Q*-RC832_RZPM:L=]-VH1JR<G"/,D(W/7C3]>YN6<0K40?D'DT&!FY4R@D
MY70P'E\;M[A#5G_.CT.VR<#1W&W@XQJJ45O1#/[2AN2GOVP6&WLO=)[*"(:(
M6W@>G]VK>+OH1+S*"744*MX'L^LV-W0EN8LP\B\@H, 9:;3#5T9^,B8C'W@A
MD?B6/O@"$0"OD*LPU!1G""U8XS&LZUC782%6Q$*L$(MAR N@@Z,Q&_4A5!.K
M;6O(NV91MWW1HM6.)&>  XXZ1837,K#8>>M:ADJTQ^FA[9B<[84<%S=\1CLV
M5BASGIP1[J$!K/",*%B7AD]T^H6G(28  !VVW;#A6_O?J6_U=D:""(4PS ]P
M0@3)W9+-D,)?,F<M3+0C"&F[)/O33:(*<,:<G2-8G#.D%GW@KLK3H?ID2'N4
MN=PM%I-I'G*([,,29SG>E7ML6AEY6NT)>AX[\8($5P>(LJ@^>\,<G[PK*#$_
M2,N"?-O> CG@H'PO'6*[>Q\0G*&*;H^)!<FC=XL4F?R L,K+A/R>VICT(!P$
M96*(OR]H_A:R93D\AP#H6".;S-]'-A !P8H-4;BCJWR7P+!*D+)3YM5"@H(!
MSG,WB[B'%;P0WXKP35R#$//EYVY<"O>E4]')XXV-A,[R)X)!F#$,\;V*AL0B
M_$#.$&N:B.-[!%)_R ]4WW $FSV#$?$[!-T@5B+.%WM!MY?.[WN4/'LM?)>+
M#8_<+"%HI<'.<Y\$2 U>Q1A#=H!LI_>+EX0\_=0H[E'-1>5OLF$&V8)+V2Y,
MRO*F1X.SH[-K(_ %LIW9*[4XH[FA> >1(H^">!6/X%0$I<&T8WL+>N[RM GR
M%LT[D\V!#XA.+&%Y0<>LP1B'!SE @NTH0X^&3ZR_OR/0V-XJ+@89D6%$KWP\
MRR3%R?V16#^"=O'I XD=]4O4_%9_!F;U>6?473BP%^6@(&;I.Y9.[>%2GL\=
MW?;6S/EM<*J_?8.8[R!$;IFY"<D;=HD]_,6_9F/?SSE/BB[K8H+IGM-V,\*U
M^ZKOVT7UP.QS?L3GJVK$5BQJBKN*JUL3KQ-L^1 C]TV1;)3)[.?3^VKZCDR*
M12F='+)1G&1S(YS1BY<8'\KF#R2N):+SMAN=SS(56+NC<R >>:YF3<LSC%DJ
MF0U(987FMTHE=N*>B]5WD2IBK(V)(;:9I/G-JY =WP@.QX:W:L L1;G/5UP&
MP:'"+^NA&F;8O6"\0\ =JCQ@YODO1(@\T&R(-X4C_JKP6=+%]\'"/,['W?R-
MZ>4\RP70S-H":.2[(M]5 XTH2WZB2NCGDV;T.R,;)\U*]ZK]S#LK/\L$_%1&
M3HI$IK40A/+-L >'6EY.\<)-[-VP;335T:9(P0[?^@J4+3@>R%=MX.*\A-(C
MD,KV^:+' 8GDU.O ,WE'AS$"'';8T+# R:C_M0'RVC?:Y.5GPL9YOQ<>TWE/
M6KO\-BIO'1"OI H]V_**B;__F->;9Q:XB!GV+HI-3B+0/V9LSRTWFV5IRDZA
ML+T5@77VQT)*R#%-8BF8F\F111A#E21J:80I0YY2_4WUZ<^92?VZM8NJ?@$2
M5?I]3'FH?.+5!?E;I&RBB3AZW@U6%^  MJ9_QP OOM0:6%%ZIO2WD&QL;[G9
MQB<*-^+:B'Y)V)P]0!>B$&&7W-O'GR:*CC.DW=#6?HK_%15QF)3_Q9[R"_]F
MR_[1G3@$)2XB!_[6"_D^.>ZJ]NG@OG*9NCQ+_5!_Z>??6P_C'NE0>T"_GY[=
M?L?J#WF8^9GMC%,/O:)]?7HV'#>?+MIXU,ZP&M;.A^,;\N.G?E9]Z/Q;;BO6
M>&@4,O2\><;.!M_,"W6ON;\W984BZ9]7;]O&R7"4NWXZ>[Q1,I/127M<O223
M_'%E.+K<&RK7Y$B54]]O[:>C:_-1K>CX6#^Z?V"C0;HXOJC1?O'[/;O.3(EZ
M_U,>GF9_#IMGXU2]3KHGE<+5WE%_,I9/;LR.\:/8OC%JZL53871*GK3SXX=)
MPYK>GM:*C=2@6OQ^V[F\^NJRXO\!4$L#!!0    ( -)#9U1P*BFPY!\  !J1
M   5    =&TR,C@U,3AD,5]E>#DY+3$N:'1M[3UI4QO)DM\5H?]0RX0=L"L)
M'8"YAGA"$D9K#*PD/#NQL;%1ZBY)-71WR7T(R[]^,[.J+QT8,Y@'+Y@/'B1U
M565EY9U9V<?G@\\7)\7"\7FGV8;_,_SO>- =7'1.CK?U_^'7;?/S\>E5^T_6
M'_QYT?E]8Z2\\)#5JM.0#:0K G8I[EA/N=PKZ2]*K"]\.=J @3#T.AX7BF]A
MF3MR[!TR7XXGX1%SN3^6\+&Z<7)\>M+Y-I%#&;*#@TKM>/L4 +E>F"+S_'MO
M&$R/'O)(]_-'UN^U  "W7M_?K>W;M?\3WPX.RC7ICJO56N6OZ7B#-2\&OV]L
MK%CSH=O-[ 8>O0?"1TYXQ)802%AK75T.FJU!_Y ASOZ36U\C*6"^("AI"+K>
M3 2A\H._ \I]AY>!3GJVP"D;C6KEP^X4(;PYD0: __.%PT.IO. ?8^D(;E<L
MY1YOWZQ ^HKEGOP<GFZ-Q<WO[)O-7_)PPCWVB<M ^"5V4^E7V&=A2_Z<T!P<
M("B;>[O5+;9;KY=K^[N-?P[&GY+R/W'?$7-VX_,2^^BH(7=^/68!BSNUO2VV
MO[M?KNXV/KP68?%7%(1R-(_%Q5FWW;D<=)L7JX7LR]R#!<0L?-K"]7FSWV$-
M-NA=7<M6OURMPTHWH* ^=P9L<-YAU[WNYV;O3]:Y;%]?=2\'Q<+5&7QY];'7
MZ?>[5Y?E)]WX6CC/>IT.Z]_TOG2_-"]8]Y)=- >=\D7WLL/.>_\!NK57+R/,
MS?Z@.>BVV&FO W^R5O.RU>F]QK-Y[]D\F!PQV/MQ]Z0?1O:<_2$=A[5@%>E%
M@H6*G2G'47?L&C0!# N*A9'RV=5,^!P>[$?^3,ZX4V*<?0+V[@M+P:3^G'4\
M>ZJD%QYO=T\0-\PL]EIPE.7!,Q4 OEA+AO,2:\$#HTJ)?>:^-=$@?"BQ>K5>
M3[=X"A!]))7)^A:@S1*I<K<J;/.2!S;_>L@^=B_:6X!DF\\9]SP5P9,V\T40
M.6' 1KYR63@1['K" Y%GH( .2P#J(S@8;\P&OK*%,YL?]V^N3][[8@Q@X)_%
MPF; +1E&WR.7#]E8S60H+.Z5)]_E?(M)CTW-R;([&4XRE.Z*D <A_&BQH2_@
M3P;#+,##W40!C):0,P!VZDN@!^'9RO*E)Q!>GT\13^U/.]M[L  9B6#.% O<
MLUEXIY"J1BKRF0,# J9&S)H(5YF1%3: +>O] 0A, F2PB(M$)0Q1:5 Y(_#@
MG"R@Q3D+X.#D"#[  ]*=^FHF7(%_PQY]-0:T!F#,E$>^$,5"8"B7;5Z?];<8
MT',0P4*3>2 MR;WW?O U4D<!@*:D)58#&?H2)@B!B$0(J."L47T'F+$C"ZTF
M7!=/SY?!+8ZWP:C <\S 4BP [FP!5H>><&F?,2G<"5\P8*T =BOB_8<3!=.I
M(=@J>!)F.4TLM>TZZW[^?%.N->KE:LW@$QX!I$4P(D2(DK,N%M8>=DP=E>,S
M,%RS+%8><5<Z\\,?,1D]&\CO0O,D<!32Y?_4_E<3Z/$V3GR"^P?9(OT #PS8
M3;K $MR!\R 2P:W=@H0)$@F3( E^548>):=JD+'$,3:<H1>$/M<'%OHP"SZ<
MI1<0<' P"S-6$@D(R(?OAP*>0\D(\Z!$-'C]&N$,2^#$.S'$S4<BG",AC$!(
MT/"8?=D=#S('72S026LFPQU(1"SRD:>8!Q@W4\$(."PO8+ #H$9##( Y<WQL
MJJ:1-N8KKTX"OW=LY,4$1;DSS# %![8#Z38O%N+=VW($\@ XJ!RJ,IPU#U<@
MI/3>I_D!E](&H]2W06Q?<S\0(,4^MTO 4?!/:R+%B$Q6$#;L"N=%%V%!RE>8
M ?8/P;@/!)V1T$B/-@\Y'1_1D/@V=10P]E0A_"A+ +K)'9\;60Q2'&%40.P\
M F[W)< >H/@<^EF9C]_0?L>^BJ;(#PG7LB8*#R CY=_B8[ D26$4-@830^&)
MD20V2B8<BKE"Q@!JMR+?UU(4MT[N(%&L9L0RRO"LJ@"9.'5$V1-C^#@3>6FB
M50"W+.$(PX)3Y#O-L&MF'#K<MD$2Z2E*L!U$+9M&(+$1"X8M8%H?G&CFPG$C
M""R,7  SG$_Q-UA6@ <BA=$ZP."C6%=5# &\5L9(Q+A>-2^_ =E@5H2!EFJ$
M[F^@9$(!"O,#J"M  TJJ_" +5$A0T=-=Y\P#;L_P$3N[E/[;#'4YFB4P("*=
M;,/?CIIF# 10:<"O^'"I6( 3\#+?((5R."!7(FT8+66$*K)'5@4S-25BC-E7
M0T$\?*ZF0G_L16-E+"_B9)"XH'F!+)3A980(B*-8:$LP:8#52NQ4H^+*LY2C
MQG.BG180#3'^ %5^P#J@XXD7&(@49*8;3Z() =('IR8;4?F>Y*S//7;FP^9D
M8"DPK$'/"-AT@+S1TBAKD3F>B [0$ %P+(F*8 *F-S%K(B)RV@+Q9=MH30"8
MJ,24'Z+Y$WEH.GG"**='F7@3/@,PA@).:"+X#%0]Z"%!4E38KY9GVK!ED-D+
M5G;&3HBU.^PUP(,!VH S!NQ&4TNY*'!<HP1 6HW +@.$O6"=F@F1_ENYS,ZD
M<.Q#UHM 1E_SL6#E\LEQN_LE'XX%=3FE\?%DY:$*0^4>(EKOI!U.#EE]]]U&
M;FC6SL.10^6#V-93G3K<NL6O6: <::>[A/$GYM\,>-LY^'X)8I\*N8^SBHT1
M7,N9P,7")Z!6+[@%"0H4YY!764T!?GKB&C1/+SJLU;FXN&ZVV]W+C[]O5#?H
M<_^ZV8H_/W)10T3WD%"M6GVW0=F,XT$O7@;$*#ET,>?"+&M86:=!C@?M>*B9
M=K?Z+C_"$:-PU5%EG9)[W/5&H\$N^"UH*5NPMH^2.Q\1:+*#G9WJ#KOI-V-O
MYO[%CKLGQZ<]V,!THCR!(1*VMUMENQ]VP(6L5AG\/N)6 'K0R?ZZSP[J>SMF
MB>/M07L9!2N"IRE6?H2#N[N[2C;2GZX#__3T06T3S;PJ88=RY B>1S/"PLUJ
MH4*86R/Z:O45LF\O(]7B[Y8$VXK,%J(VW:B6=LO+HP*^+0\%Z&N <4HP9T':
M6P$1@OFS2V;%["^5L"]#NCQ2LBQ+E49CI5318<#?]NN-@S@.J#GF(3RY]P$@
MQ$/0F*L;GB9N2SGMY?'9&K09&3KA8%6AC:57Y;$+J3_Z HU4AL&O,^6[^LO]
M\B<P<SEZF983V>CD4O2"+%L?O$6,::$A'B@7I&_SO^A;\B#)]Q4P$!C'Y6G@
M328#C2,S6/T4".'<*F!R1XZ-%J"/FX&GP,[[*_)T3,\$WC0,SV'VK4#TW\B'
M)8X#GI&GT/D'\UX[X8#+(7H[\US<80PR<ZZ=QY!"GF#^4Y0L&S]<ZTA46!=,
M;!.D(B<< R?<FI-WD4(@8/#0D<'$."QT?&G$H9)X/,4"0L[9J?H&C_[!P<<"
MBUS'(V88)%7HX(]$.9R0HT(_>R(*?? )T1\C(M*/VI+[/K@V1VQJCEX(  >S
M'131LVV)BX.EWTT<JSYMI5CHIH3T@HW_E7P*.@QT%H:*/+N,/JY_"/X>>-R4
MZSB^.6D.510NA$^+!4H/Z>S_+TO&_1C"P8J@;K$@D23&E%4NZ0"03G&5&)YZ
MV>%PJJ4DC4*#2@R<<AL<NN] 1[7#&@7'=+!.I/[U3Z8%BH5-V.,P BN^!!PP
M%98$NI:>*+&Q<-,/0%TSZ8&B=_ S96%V=QJ/<],I-0 B;"95%("/;AQT$SE^
M2&*&/2PO8Y3<RCP%R>I\BB4)?H. !5![(I@J#_#?,1%1$*8M7V*@G^/^^V@^
ML0'&[ *VV>NTNOT!JU5J6PSY/0A@9BV@0$QX-D6X;0&'BT43E-#T@4\1"^+.
MA#Q0V<LI1WSF<9*<+ABY\%BL0S"98A[4!W!_PB=X1+Z'Q>D>'0A%K"D\/X+
M%J&PPGNS6AC/UA$'BMN%S"%JJ%8.F O\-T&92>$)[K'KLWXEDX^-CRJ(56R<
MI$A3825F1[X^&9C=-P<&A!P'O^)(,89NB6CB/$?\K/D%0\[P;7)PL;[(Z(%0
M801X*!VIOR@6OD;<,>$S%."P#0Z 84C],\;(LYJ;DX#*B 'D_QF7P.>.0+2
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M#SE*^415P1_23[1-QO:<:H$;)+D"F"4 4\\19;18P[SL)D\CA34GY->.TLA
MX0UG1\Z$RZ6'$EOYK\WDRS-[4BKR3,R]KC2%W5>98HPZ*@@H@W]O.:!+$/1I
MN0[TBLD:3!]ZH1PJ>UZV_6BL'340 J(2/TAS6$*GXD%D"!HQQI0&..+ .N(;
M>7\Z8[XJ=5C";#(J3'0D\!E41E0E>J"%@"%OY+=\IC)(O19&W@QE<-"?H+P8
MZO68"#G2&9 Y, W0^61N^\J9?R=M!NKK%@52&(+$0!,&*+U_66[L8\E5J$"G
MHTOLHZ'136TZ(/:YH[B-9@NL'7GR:X0%)"[8FUJ' ER4L3*9I21Y3MEEI:TD
MQ*!!$.X>\6B,1:S5<*7E*^'-I*\\Y,K7QQ39XTE\X-P9-W89*0%?$B708254
MDG$0,QZSMD$1YT *=WR>"OV2<6T7O&ANPX0+DC3R,/MDA9H$E+8$X]PK50T]
M-.7.-@>7IZVM)*.75FZAQ8\3406"+C"9!Z%P<482@;K6)#8R43_IG+E+^T@!
M*!:,_L@3/)A;*H=6RI-B236AACZN+ 4P11 /QY9!$!C5!D,LCZ#(1Z'N4 ;9
M(.4FBY*,]Y1@!U@2E9\7N6 V>2&(?F*!; *:XAD2/VD;G[M@>L?V?6+)U-CF
M=;L,?HQ:?JP,!(FSZ&<N:ELI![]R;L*S'PI$F:D B#/1<1X;Q2I>,Y!C;G@H
M"L@ (O0R)%I"<.88;UJ9JATDS8R?@=[\6!-HINSC;H+.<:H+%H5^B26RO5B8
M_*0-RAYH@JXSA4K97SSPF@.7#$I25TZ$U&:(];+?NFAMY9ZG9]GRH^;)"88N
MJ4Q,6+?)>D2P&/00VI$U,;I?1VDO(@/PEE]\E?G%ER?W'I9=K+]E%]^RBR\Q
MN]AXY=E%[<*2 =E-,D.Y<KCG<FB[7ESSAW9K'S0R3I!W]@A ;?0L9\X.?Y**
M_^BV!^>_;Q#-_4V27E7316Q^+R6O)EJ2B'EJC'^IU'>E=U]Y5'_N#I4#M.-*
MVU;A44X;K*;N!/_-G_68%OP!,BX?X! 5"X_TB.* 6B55;D]<./-&0$]-0#^@
MF9O6(_Q%,.8?Z#"RO^TOZDA/FC//!C6*!>URKW2W=<P50^'D.2WD<F"U55FA
M2G)',#/3BLP]U8,/Z>X27H*@*RT1S("95<IJZ80.KB("RY?3>*&EI!/=7<*2
M6XEI($7Q8'!B?AV+O8CTC%9W<?E!L:#K#UBF_."?H@$!N-.K_^ZTV1_-WB4(
MF4-VV;G!A%SGLMMDS<LV:W>;O=YYIYF#YDU8/4)8 :[[#ZMM05Y3EA6!,/@#
MQ,Q$.79JE5 6:PA^1 1L;49-I*/CF[KLI5BH[5:KVZY+D?J&B=+#N'01BXT0
M%DS*>A1H'CI*V3H08=)E4S@'99OL-<@.NOL4&S\D-]#1]=G'<JM_EKE*A*%O
M#(-/Y@[_)H,*%MG(4&HI%,JR]$;"HNA*:DHM75\=B:&/=^JR:,$?,.\!>.#S
MBB;(-[7\HBD]+LW*DG1,<?D#3YY$'3)&ZA@YD=3!+]!U5HBIE!"O@ 5T'T;8
M0%A-VP7M0B$6CF1"13ER1/5HJ*E\GACP.FBO$[K)6AB']N:ZCDR&\PIKZGHI
MU(P4I<;2Q.3Q4EI8A',9.@;[ <P#'@7Z>II>W\0/2\@([C1T\,JNX0&,H8(M
M *P#"F&T6,.FD02T<;?$^,"4DDHTE#/3F=+WCCCZZ'-;@"%!M1=4PR*R-UAM
MS%?_6EYYSA8:@UZS>]GNMIJ#[M5E_TTG_5U.-6PZF0--!GB;S20/03#K6BB@
MLI@ 7[>%1A1DK)P^63;7O4ZK>;-,2+]N^<M4F>FN41K]I25KH$2IP1$/P6[.
M:D"+>UI Z)0*QX/Z&DF4'UCUYH*Z'B6EMIG5]"!?I^_V:N^R5XOS913)83,2
M+,5"H[R3 R$[T\Z'=_E+RF<KM'9VP(=W3VO1>*P-.*C%<MR:6X[(V#D+DV"L
M;]T<^[DYUD&9L9^*!6U O;KT'M!AVRB;0VKHTLZIGIA(=M/*J =1"D-"L5=-
M5:LO4,F5EUY:GU!I?H@)1,P=@A@"/,?^$+9EH-2CF18T_F7&@@4_"^15D%NL
M6ME=6&WU2:Z &5D*+Y.Z O.-WCI-BT8"L"=:"&L- I;: P\W!TILA[EC\PO:
MW$E?BN&<U?$G70D,5#?')&:@D#^I0-7L0/>O<,'J=B,7L5#;PV$V!SU1@7,.
MK+@?4+HJ' \#JQJKAT=H1R63F>UCZX&T/B*(INC"HGD6UW6R35$95T!BK;37
MR!8)91CA!%LDLDQ.F0EWZJ@YQAV")$I F#$66[93QP0['N@NA9C!_69A*0L
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M,C R,C S,#<N>'-D4$L! A0#%     @ TD-G5"_BJF#_"@  ;(<  !4
M         ( !:@,  &=I;&0M,C R,C S,#=?;&%B+GAM;%!+ 0(4 Q0    (
M -)#9U0;(A-/4P<  +U8   5              "  9P.  !G:6QD+3(P,C(P
M,S W7W!R92YX;6Q02P$"% ,4    " #20V=4Y"#B2YH3  #?;   $0
M        @ $B%@  =&TR,C@U,3AD,5\X:RYH=&U02P$"% ,4    " #20V=4
M<"HIL.0?   :D0  %0              @ 'K*0  =&TR,C@U,3AD,5]E>#DY
M+3$N:'1M4$L! A0#%     @ TD-G5*D2H0/G"P  MCT  !4
M ( ! DH  '1M,C(X-3$X9#%?97@Y.2TR+FAT;5!+!08     !@ & (H!   <
%5@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
